171 related articles for article (PubMed ID: 35427833)
1. Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.
Haag GM; Springfeld C; Grün B; Apostolidis L; Zschäbitz S; Dietrich M; Berger AK; Weber TF; Zoernig I; Schaaf M; Waberer L; Müller DW; Al-Batran SE; Halama N; Jaeger D
Eur J Cancer; 2022 May; 167():112-122. PubMed ID: 35427833
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis.
Kuang C; Park Y; Augustin RC; Lin Y; Hartman DJ; Seigh L; Pai RK; Sun W; Bahary N; Ohr J; Rhee JC; Marks SM; Beasley HS; Shuai Y; Herman JG; Zarour HM; Chu E; Lee JJ; Krishnamurthy A
Clin Epigenetics; 2022 Jan; 14(1):3. PubMed ID: 34991708
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer.
Yoshino T; Andre T; Kim TW; Yong WP; Shiu KK; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Alcaide-Garcia J; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Le DT; Adachi N; Fogelman D; Marinello P; Diaz LA
Cancer Sci; 2023 Mar; 114(3):1026-1036. PubMed ID: 36369901
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.
Yarchoan M; Huang CY; Zhu Q; Ferguson AK; Durham JN; Anders RA; Thompson ED; Rozich NS; Thomas DL; Nauroth JM; Rodriguez C; Osipov A; De Jesus-Acosta A; Le DT; Murphy AG; Laheru D; Donehower RC; Jaffee EM; Zheng L; Azad NS
Cancer Med; 2020 Feb; 9(4):1485-1494. PubMed ID: 31876399
[TBL] [Abstract][Full Text] [Related]
6. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer.
Kim DW; Tan E; Zhou JM; Schell MJ; Martinez M; Yu J; Carballido E; Mehta R; Strosberg J; Imanirad I; Kim RD
Br J Cancer; 2021 May; 124(11):1803-1808. PubMed ID: 33828254
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.
Cartwright E; Slater S; Saffery C; Tran A; Turkes F; Smith G; Aresu M; Kohoutova D; Terlizzo M; Zhitkov O; Rana I; Johnston EW; Sanna I; Smyth E; Mansoor W; Fribbens C; Rao S; Chau I; Starling N; Cunningham D
ESMO Open; 2024 Apr; 9(4):102971. PubMed ID: 38518549
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
10. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
Garralda E; Sukari A; Lakhani NJ; Patnaik A; Lou Y; Im SA; Golan T; Geva R; Wermke M; de Miguel M; Palcza J; Jha S; Chaney M; Abraham AK; Healy J; Falchook GS
ESMO Open; 2022 Dec; 7(6):100639. PubMed ID: 36493599
[TBL] [Abstract][Full Text] [Related]
11. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
Le DT; Kim TW; Van Cutsem E; Geva R; Jäger D; Hara H; Burge M; O'Neil B; Kavan P; Yoshino T; Guimbaud R; Taniguchi H; Elez E; Al-Batran SE; Boland PM; Crocenzi T; Atreya CE; Cui Y; Dai T; Marinello P; Diaz LA; André T
J Clin Oncol; 2020 Jan; 38(1):11-19. PubMed ID: 31725351
[TBL] [Abstract][Full Text] [Related]
12. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer.
Gomar M; Najafi M; Aghili M; Cozzi S; Jahanbakhshi A
Daru; 2021 Dec; 29(2):501-506. PubMed ID: 34254265
[TBL] [Abstract][Full Text] [Related]
13. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA
N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164.
Le DT; Diaz LA; Kim TW; Van Cutsem E; Geva R; Jäger D; Hara H; Burge M; O'Neil BH; Kavan P; Yoshino T; Guimbaud R; Taniguchi H; Élez E; Al-Batran SE; Boland PM; Cui Y; Leconte P; Marinello P; André T
Eur J Cancer; 2023 Jun; 186():185-195. PubMed ID: 37141828
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.
Gallois C; Emile JF; Kim S; Monterymard C; Gilabert M; Bez J; Lièvre A; Dahan L; Laurent-Puig P; Mineur L; Coriat R; Legoux JL; Hautefeuille V; Phelip JM; Lecomte T; Sokol H; Capron C; Randrian V; Lepage C; Lomenie N; Kurtz C; Taieb J; Tougeron D
Dig Liver Dis; 2021 Oct; 53(10):1254-1259. PubMed ID: 34215534
[TBL] [Abstract][Full Text] [Related]
18. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
19. Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.
Segal NH; Cercek A; Ku G; Wu AJ; Rimner A; Khalil DN; Reidy-Lagunes D; Cuaron J; Yang TJ; Weiser MR; Romesser PB; Stadler ZK; Varghese AM; Ganesh K; Yaeger R; Connell LC; Faleck D; Abou-Alfa GK; Mcauliffe KC; Vaiskauskas P; Solter ML; Ogle M; Adamow MJ; Holland A; Vedantam P; Wong P; Merghoub T; Vakiani E; Hollmann TJ; Juluru K; Chou JF; Capanu M; Erinjeri J; Solomon S; Yamada Y; Kemeny N; Crane CH; Saltz LB
Clin Cancer Res; 2021 Apr; 27(8):2200-2208. PubMed ID: 33504552
[TBL] [Abstract][Full Text] [Related]
20. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer.
Kim RD; Kovari BP; Martinez M; Xie H; Sahin IH; Mehta R; Strosberg J; Imanirad I; Ghayouri M; Kim YC; Kim DW
Eur J Cancer; 2022 Jul; 169():93-102. PubMed ID: 35526308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]